Chinese Journal of Dermatology ›› 2023, e20210730.doi: 10.35541/cjd.20210730

• Reviews • Previous Articles     Next Articles

Dupilumab in the treatment of childhood atopic dermatitis

Tian Jing, Liang Yuan, Ma Lin   

  1. Department of Dermatology, Beijing Children′s Hospital, Capital Medical University, National Center for Children′s Health, China, Beijing 100045, China
  • Received:2021-10-08 Revised:2022-02-07 Online:2023-01-05 Published:2023-03-01
  • Contact: Ma Lin
  • Supported by:
    National Natural Science Foundation of China (81673042); The Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals(XTZD20180502)

Abstract: 【Abstract】 Currently, childhood atopic dermatitis (AD) is mainly treated by regular use of moisturisers in combination with topical glucocorticoids or calcineurin inhibitors. For some children with refractory moderate-to-severe AD, systemic glucocorticoids or off-label use of other immunomodulators may be required; however, these treatments usually have some limitations and adverse effects. In recent years, with the discovery of key inflammatory factors in AD, dupilumab, a biological agent targeting interleukin-4/13, has been widely used in clinical practice, and shown certain efficacy. This review summarizes recent clinical studies on dupilumab in the treatment of AD in children.

Key words: Dermatitis, atopic, Child, Therapy, Biological agents, Dupilumab